This article was originally published on 7 September 2016 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
BARDA investments signal urgency
The Zika virus outbreak that swept through the Americas in 2015-2016 brought renewed urgency to flavivirus vaccine development. Two significant BARDA funding awards dominated the headlines during mid-2016: a contract worth up to $21.9 million awarded to Emergent BioSolutions and a much larger commitment of up to $312 million awarded to Takeda Pharmaceuticals - signalling that the US government was prepared to back multiple platforms simultaneously.
Total US BARDA funding allocated to Emergent BioSolutions and Takeda Zika vaccine programmes in 2016
Phase I candidates advance
At the clinical stage, the US National Institute of Allergy and Infectious Diseases (NIAID) was advancing a DNA-based Zika vaccine candidate into Phase I trials. Inovio Pharmaceuticals, with strong prior experience in DNA vaccine platforms, also had a Phase I candidate underway. Both programmes reflected a broader industry shift towards nucleic acid vaccine technologies that had been pioneered for other flaviviruses and emerging pathogens.
Takeda's approach drew on its prior experience with dengue vaccine development through its DENVax programme (acquired via Inviragen in 2013), providing it with relevant flavivirus expertise. The sizeable BARDA contract demonstrated confidence in the company's manufacturing capacity and platform.
"The unusual epidemiology of Zika - a self-limiting outbreak with waning population susceptibility - creates real challenges for demonstrating vaccine efficacy in a Phase III trial."
Commercial and epidemiological challenges
Despite the accelerating pipeline, Zika vaccine development faces a complication that distinguishes it from many other vaccine programmes: the outbreak may be largely self-limiting. As herd immunity builds across affected populations, the window for conducting a traditional efficacy trial - which requires sufficient circulating virus to observe cases in an unvaccinated control group - may be narrowing. This has prompted discussion of alternative trial designs, including human challenge models and immunogenicity-based endpoints.
The commercial case is also nuanced. The primary burden of serious disease is congenital Zika syndrome in infants born to infected mothers, suggesting that pregnant women and women of childbearing age in endemic regions represent the core target population. Vaccine safety requirements for use in pregnant women are particularly stringent, potentially extending development timelines.
Outlook
The level of investment and the breadth of platforms being evaluated - DNA, mRNA, live-attenuated, subunit, and VLP approaches - represents an encouraging diversification of risk. The Zika outbreak has also demonstrated the ability of regulators and funders to fast-track development when political and public health pressure is sufficient. Whether a commercially viable Zika vaccine will ultimately reach market remains to be seen, but the scientific and funding infrastructure assembled in 2016 has materially strengthened the case.